PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
- First Posted Date
- 2004-08-11
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT00089648
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Dallas, Texas, United States
Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00004199
- Locations
- ๐บ๐ธ
Agouron Pharmaceuticals, Inc., La Jolla, California, United States
Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer
- Conditions
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 525
- Registration Number
- NCT00003343
- Locations
- ๐บ๐ธ
Agouron Pharmaceuticals, Inc., La Jolla, California, United States
Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Conditions
- First Posted Date
- 2004-07-13
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1077
- Registration Number
- NCT00087490
- Locations
- ๐ป๐ช
Pfizer Investigational Site, Valencia, Venezuela
Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy
- Conditions
- First Posted Date
- 2004-07-13
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT00087503
- Locations
Pfizer Investigational Site
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00005093
- Locations
- ๐บ๐ธ
New England Medical Center Hospital, Boston, Massachusetts, United States
๐จ๐ฆBC Cancer Agency, Vancouver, British Columbia, Canada
๐บ๐ธUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
- Conditions
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00004861
- Locations
- ๐บ๐ธ
Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธIreland Cancer Center, Cleveland, Ohio, United States
๐บ๐ธSinai Hospital of Baltimore, Baltimore, Maryland, United States
SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00003720
- Locations
- ๐บ๐ธ
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธKaplan Cancer Center, New York, New York, United States
๐บ๐ธJonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1225
- Registration Number
- NCT00084266
- Locations
Pfizer Investigational Site
Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia
- Conditions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2008-11-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00084240